Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib with Docetaxel in Hormone Refractory Prostate Cancer
NCT00996502Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jul 2006
- Primary completion
- Mar 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in prostate cancer (PCa), sponsored by Columbia University. Started Jul 2006; status: terminated.
02
Drugs
bevacizumaberlotinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00996502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996502.